Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Retained Earnings: 2019-2024

Historic Retained Earnings for Fulcrum Therapeutics (FULC) over the last 6 years, with Dec 2024 value amounting to -$519.4 million.

  • Fulcrum Therapeutics' Retained Earnings fell 14.14% to -$573.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$573.9 million, marking a year-over-year decrease of 14.14%. This contributed to the annual value of -$519.4 million for FY2024, which is 1.91% down from last year.
  • According to the latest figures from FY2024, Fulcrum Therapeutics' Retained Earnings is -$519.4 million, which was down 1.91% from -$509.7 million recorded in FY2023.
  • Fulcrum Therapeutics' Retained Earnings' 5-year high stood at -$221.6 million during FY2020, with a 5-year trough of -$519.4 million in FY2024.
  • Its 3-year average for Retained Earnings is -$480.5 million, with a median of -$509.7 million in 2023.
  • Data for Fulcrum Therapeutics' Retained Earnings shows a maximum YoY plummeted of 46.96% (in 2020) over the last 5 years.
  • Fulcrum Therapeutics' Retained Earnings (Yearly) stood at -$221.6 million in 2020, then slumped by 36.49% to -$302.5 million in 2021, then crashed by 36.31% to -$412.3 million in 2022, then decreased by 23.61% to -$509.7 million in 2023, then dropped by 1.91% to -$519.4 million in 2024.